MedDataX Logo

INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy

NCT ID: NCT00153088

Last Updated: 2013-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

527 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-01-31

Study Completion Date

2005-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to compare the preventive effect of Telmisartan(Micardis) versus placebo control on the transition to overt nephropathy in patients with diabetic nephropathy manifesting microalbuminuria associated with type II diabetes, and to evaluate the efficacy and safety of Telmisart (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) for diabetic nephropathy patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A prospective, randomised, double-blind, multicentric and comparative study to investigate, on a long-term basis, the preventive effect on the transition to overt nephropathy and the safety of Telmisartan (Micardis) against placebo in patients with diabetic nephropathy, manifesting microalbuminuria associated with type II diabetes.

Study Hypothesis:

The hypothesis is that Telmisartan (Micardis) at 40 mg or 80 mg versus placebo control in patients with concurrent type II diabetic mellitus or diabetic nephropathy demonstrating microalbuminuria, has the preventive effect on transition from incipient to overt nephropathy.

Comparison(s):

The primary endpoint is defined as the transition from incipient to overt nephropathy, and the non-transition curve will be demonstrated based on the Kaplan-Meier method. The evaluation criteria for the point to transition to overt nephropathy is defined as urinary albumin to creatinine ratios at consecutive 2 measuring points increasing over 300 mg/g-Creatinine and excess 30% increase comparing with the baseline value. The curve of non-transition will be compared with Logrank test. Those in BIBR277 groups are sequentially compared with that in the placebo group by the closed testing procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Nephropathies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telmisartan capsule 40 mg

Intervention Type DRUG

Placebo

Intervention Type DRUG

Telmisartan capsule 80 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Outpatients who are able to visit the study site throughout the run-in period
2. Aged 30 and 74 years
3. Type II diabetes mellitus
4. Patients with urinary albumin to creatinine ratios within the following ranges at 2 measuring points during the run-in period 1) the first-morning voided urine, iin the range of 100 to 300 mg/g Creatinine 2) \< 100 mg/g Creatinine at either point of Visit 2 or 3, but in the range of 100 to 300 mg/g Creatinine at follow-up
5. Serum creatinine level of \< 1.5 mg/dL in male and \< 1.3 mg/dL in female
6. Normotensive or hypertensive patients
7. Patients taking AT1 antagonists or ACE inhibitors at screening, but are able to stop those drugs during the study
8. Patients who are able to provide written informed consent in accordance with the Good Clinical Practice (GCP) and other relevant laws such as the Pharmaceutical Affairs Law

Exclusion Criteria

1. Age of onset of type 2 diabetes is \< 30 years
2. Type I diabetes
3. Urinary albumin to creatinine ratio of \> 300 mg/g Creatinine
4. HbA1c 9%
5. Seated SBP 180 mmHg or DBP 110 mmHg
6. Findings suggesting a renal disease other than diabetic nephropathy; such as post renal transplantation, history of non-diabetic renal disease, marked haematuria, complication of urinary tract infection
7. Cardiovascular diseases:

* Patients with unstable angina, myocardial infarction, CABG, PTCA within 6 months before
* CHF with NYHA III-IV
* TIA within 6 months
* Stroke within 6 months
* AV block (grade II-III) or AF
* Serious arrhythmia
* Known or suspected secondary HT
8. History of angioedema during administration of ARB/ACE-i
9. Hypersensitivity
10. History of sudden exacerbation of renal function due to ARB/ACE-i
11. Markedly poor bile secretion
12. Hepatic dysfunction: SGPT (ALT) or SGOT (AST) 100 IU/L
13. Serum potassium level \< 3.5 mEq/L or 5.1 mEq/L
14. Unable to discontinue ARB/ACE-i
15. Require prolonged administration of any medications affecting blood pressure, except diuretics, or blockers, and CCB
16. Untreated sodium depletion
17. Pre-menopausal females who meet any one of the following:

* Pregnant or possibly pregnant
* Breast-feeding
* Hope to be pregnant during the study period
* Even when a patient is confirmed not to meet the above criteria at the start of the study, a female patient who has the potential to be pregnant during the study is to undergo pregnancy tests. If the result turns positive, the study medication should be discontinued.
18. Malignant tumour or other diseases requiring oral or injection immunosuppressants
19. Non-compliance
20. History of drug or alcohol abuse
21. Participated in other clinical studies within 3 months
22. Any other conditions investigators judged as ineligible
Minimum Eligible Age

30 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim Study Coordinator

Role: STUDY_CHAIR

Nippon Boehringer Ingelheim Co., Ltd.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigational Site

Adachi-ku, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Amagasaki, Hyogo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Arakawa-ku, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Asaguchi-gun, Okayama, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Asahi, Chiba, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Asahikawa, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Asahikwa, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Atami, Shizuoka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Atsugi,Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Chikugo, Fukuoka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Chisagata-gun, Nagano, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Chisagata-gun, Nagano, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Chitose, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Chiyoda, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Chiyoda-ku, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Chiyoda-ku, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Ebina, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Fujisawa, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Fukuoka, Fukuoka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Fukuoka, Fukuoka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Fukuoka, Fukuoka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Fukuyama, Hiroshima, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Funabashi, Chiba, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Furukawa, Miyagi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Gifu, Gifu, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Gobo, Wakayama, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Hachioji, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Hakodate, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Hanamaki, Iwate, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Hannan, Osaka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Hashima-gun, Gifu, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Hatsukaichi, Hiroshima, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Hirakata, Osaka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Hitachiota, Ibaragi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Ichinomiya, Aichi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Iida, Nagano, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Ikeda, Osaka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Inashiki-gun, Ibaragi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Isehara, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Isezaki, Gunma, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Itami, Hyogo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Izumisano, Osaka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kamakura, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kamakura, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kamogawa, Chiba, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Katsushika-ku, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kawagoe, Saitama, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kawaguchi, Saitama, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kawasaki, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kawasaki, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kawasaki, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kawasaki, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kawasaki, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kawasaki, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kisarazu, Chiba, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kita-katushika-gun, Saitama, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kita-ku, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kitami, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kobe, Hyogo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kobe, Hyogo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kochi, Kochi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kochi, Kochi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kodaira, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kodaira, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Komaki, Aichi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Komatsushima, Tokushima, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Koriyama, Fukushima, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Koriyama, Fukushima, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Koriyama,Fukushima, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kounan, Aichi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kumagaya, Saitama, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kurashiki, Okayama, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kurashiki, Okayama, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Kyoto, Kyoto, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Matsuyama, Ehime, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Matsuyama, Ehime, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Minato-ku, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Minato-ku, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Minato-ku, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Musashino, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nagoya, Aichi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nagoya, Aichi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nagoya, Aichi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nagoya, Aichi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nagoya, Aichi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nagoya, Aichi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nagoya, Aichi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nakano-ku, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nangoku, Kochi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nishinomiya, Hyogo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nishinomiya, Hyogo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nishinomiya, Hyogo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Noda, Chiba, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Nomi, Ishikawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Obihiro, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Odawara, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Oita, Oita, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Okawa, Fukuoka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Okayama, Okayama, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Okayama, Okayama, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Okayama, Okayama, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Osaka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Osaka, Osaka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Osaka, Osaka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Osaka, Osaka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Osaka-sayama, Osaka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Otaru, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Oyama, Tochigi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sagamihara, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sagamihara, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sakai, Osaka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sakai, Osaka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sapporo, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sapporo, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sapporo, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sapporo, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sapporo, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sapporo, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sapporo, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sapporo, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sapporo, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sapporo, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sapporo, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sapporo, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sapporo, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sendai, Miyagi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sendai, Miyagi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Setagaya-ku, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Seto, Aichi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Shibetsu, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Shibuya-ku, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Shibuya-ku, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Shinagawa, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Shinjuku-ku, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Shinjyuku-ku, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Shiojiri, Nagano, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Sunagawa, Hokkaido, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Takamatsu, Kagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Takarazuka, Hyogo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Takasaki, Gunma, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Takatsuki, Osaka, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Tama, Tokyo, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Toride, Ibaraki, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Tosu, Saga, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Toyohashi, Aichi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Toyohashi, Aichi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Toyota, Aichi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Tsuchiura, Ibaraki, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Tsuchiura,Ibaraki, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Tsukuba, Ibaragi, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Uji, Kyoto, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Ushiku, Ibaraki, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Uwajima, Ehime, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Yokohama, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Yokohama, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Yokohama, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Yokohama, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Yokohama, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Yokohama, Kanagawa, , Japan

Site Status

Boehringer Ingelheim Investigational Site

Yokohama, Kanagawa, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

502.413

Identifier Type: -

Identifier Source: org_study_id